{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:15:20Z","timestamp":1774307720799,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1124\/jpet.107.119693","type":"journal-article","created":{"date-parts":[[2007,5,15]],"date-time":"2007-05-15T00:59:05Z","timestamp":1179190745000},"page":"749-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects"],"prefix":"10.1016","volume":"322","author":[{"given":"Lawrence P.","family":"Carter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia E.","family":"Suess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Casada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Roache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.107.119693_bib1","doi-asserted-by":"crossref","unstructured":"Ator NA (2000) Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons. Drug Alcohol Depend 24: 55\u201368.","DOI":"10.1016\/S0376-8716(00)00123-X"},{"key":"10.1124\/jpet.107.119693_bib2","doi-asserted-by":"crossref","unstructured":"Evans SM, Funderburk FR, and Griffiths RR (1990) Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 255: 1246\u20131255.","DOI":"10.1016\/S0022-3565(25)23193-7"},{"key":"10.1124\/jpet.107.119693_bib3","doi-asserted-by":"crossref","unstructured":"Foster AC, Pelleymounter MA, Cullen MJ, Lewis D, Joppa M, Chen TK, Bozigian HP, Gross RS, and Gogas KR (2004) In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J Pharmacol Exp Ther 311: 547\u2013559.","DOI":"10.1124\/jpet.103.063487"},{"key":"10.1124\/jpet.107.119693_bib4","doi-asserted-by":"crossref","unstructured":"Griffiths RR, Bigelow GE, and Ator NA (2003) Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 70: S41\u2013S54.","DOI":"10.1016\/S0376-8716(03)00098-X"},{"key":"10.1124\/jpet.107.119693_bib5","unstructured":"Griffiths RR and Johnson MW (2005) Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 9: 31\u201341."},{"key":"10.1124\/jpet.107.119693_bib6","doi-asserted-by":"crossref","unstructured":"Griffiths RR, Lamb RJ, Ator NA, Roache JD, and Brady JV (1985) Relative abuse liability of triazolam: experimental assessment in animals and humans. Neurosci Biobehav Rev 9: 133\u2013151.","DOI":"10.1016\/0149-7634(85)90039-9"},{"key":"10.1124\/jpet.107.119693_bib7","doi-asserted-by":"crossref","unstructured":"Griffiths RR, Sannerud CA, Ator NA, and Brady JV (1992) Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 260: 1199\u20131208.","DOI":"10.1016\/S0022-3565(25)11429-8"},{"key":"10.1124\/jpet.107.119693_bib8","doi-asserted-by":"crossref","unstructured":"Griffiths RR, Troisi JR, Silverman K, and Mumford GK (1993) Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4: 3\u201313.","DOI":"10.1097\/00008877-199302000-00001"},{"key":"10.1124\/jpet.107.119693_bib9","doi-asserted-by":"crossref","unstructured":"Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man), in Drug Addiction I, Springer-Verlag, New York.","DOI":"10.1007\/978-3-642-66612-4_4"},{"key":"10.1124\/jpet.107.119693_bib10","doi-asserted-by":"crossref","unstructured":"Licata SC, Platt DM, Cook JM, Sarma PV, Griebel G, and Rowlett JK (2005) Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1 H-pyridol[3,4-b]indol-1-one]. J Pharmacol Exp Ther 313: 1118\u20131125.","DOI":"10.1124\/jpet.104.081612"},{"key":"10.1124\/jpet.107.119693_bib11","doi-asserted-by":"crossref","unstructured":"L\u00f6w K, Crestani F, Keist R, Benke D, Br\u00fcnig I, Benson JA, Fritschy J-M, R\u00fclicke T, Bluethmann H, M\u00f6hler H, et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290: 131\u2013134.","DOI":"10.1126\/science.290.5489.131"},{"key":"10.1124\/jpet.107.119693_bib12","doi-asserted-by":"crossref","unstructured":"Lydiard BR, Lankford DA, Seiden DJ, Landin R, Farber R, and Walsh JK (2006) Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial. J Clin Sleep Med 2: 309\u2013315.","DOI":"10.5664\/jcsm.26591"},{"key":"10.1124\/jpet.107.119693_bib13","doi-asserted-by":"crossref","unstructured":"Martin WR, Sloan JW, Sapiro JD, and Jasinski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12: 245\u2013258.","DOI":"10.1002\/cpt1971122part1245"},{"key":"10.1124\/jpet.107.119693_bib14","doi-asserted-by":"crossref","unstructured":"McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor \u03b11 subtype. Nat Neurosci 3: 587\u2013592.","DOI":"10.1038\/75761"},{"key":"10.1124\/jpet.107.119693_bib15","doi-asserted-by":"crossref","unstructured":"McLeod D, Griffiths RR, Bigelow GE, and Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14: 463\u2013466.","DOI":"10.3758\/BF03203313"},{"key":"10.1124\/jpet.107.119693_bib16","doi-asserted-by":"crossref","unstructured":"McMahon LR, Gerak LR, Carter L, Ma C, Cook JM, and France CP (2002) Discriminative stimulus effects of benzodiazepine (BZ)1 receptor-selective ligands in rhesus monkeys. J Pharmacol Exp Ther 300: 505\u2013512.","DOI":"10.1124\/jpet.300.2.505"},{"key":"10.1124\/jpet.107.119693_bib17","unstructured":"McNair DM, Lorr M, and Droppleman LF (1971) Profile of Mood States (Manual), Educational and Industrial Testing Service, San Diego, CA."},{"key":"10.1124\/jpet.107.119693_bib18","doi-asserted-by":"crossref","unstructured":"Mehta AK and Ticku MK (1999) An update on GABAA receptors. Brain Res Brain Res Rev 29: 196\u2013217.","DOI":"10.1016\/S0165-0173(98)00052-6"},{"key":"10.1124\/jpet.107.119693_bib19","doi-asserted-by":"crossref","unstructured":"Mintzer MZ, Frey JM, and Griffiths RR (1998) Zolpidem is differentiated from triazolam in humans using a three-response drug discrimination procedure. Behav Pharmacol 9: 545\u2013559.","DOI":"10.1097\/00008877-199811000-00010"},{"key":"10.1124\/jpet.107.119693_bib20","doi-asserted-by":"crossref","unstructured":"Mintzer MZ and Griffiths RR (1998) Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability. Drug Alcohol Depend 53: 49\u201366.","DOI":"10.1016\/S0376-8716(98)00110-0"},{"key":"10.1124\/jpet.107.119693_bib21","doi-asserted-by":"crossref","unstructured":"Mumford GK, Rush CR, and Griffiths RR (1995) Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 272: 570\u2013580.","DOI":"10.1016\/S0022-3565(25)24438-X"},{"key":"10.1124\/jpet.107.119693_bib22","doi-asserted-by":"crossref","unstructured":"Paronis CA, Cox ED, Cook JM, and Bergman J (2001) Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys. Psychopharmacology 156: 461\u2013468.","DOI":"10.1007\/s002130100754"},{"key":"10.1124\/jpet.107.119693_bib23","doi-asserted-by":"crossref","unstructured":"Petroski RE, Pomeroy JE, Das R, Bowman H, Yang W, Chen AP, and Foster AC (2006) Indiplon is a high-affinity positive allosteric modulator with selectivity for \u03b11 subunit-containing GABAA receptors. J Pharmacol Exp Ther 317: 369\u2013377.","DOI":"10.1124\/jpet.105.096701"},{"key":"10.1124\/jpet.107.119693_bib24","doi-asserted-by":"crossref","unstructured":"Platt DM, Rowlett JK, Spealman RD, Cook J, and Ma C (2002) Selective antagonism of the ataxic effects of zolpidem and triazolam by the GABAA\/\u03b11-preferring antagonist \u03b2-CCt in squirrel monkeys. Psychopharmacology 164: 151\u2013159.","DOI":"10.1007\/s00213-002-1189-9"},{"key":"10.1124\/jpet.107.119693_bib25","doi-asserted-by":"crossref","unstructured":"Rowlett JK, Platt DM, Lelas S, Atack JR, and Dawson G (2005) Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad SciUSA 102: 915\u2013920.","DOI":"10.1073\/pnas.0405621102"},{"key":"10.1124\/jpet.107.119693_bib26","doi-asserted-by":"crossref","unstructured":"Rowlett JK, Spealman RD, and Lelas S (1999) Discriminative stimulus effects of zolpidem in squirrel monkeys: comparison with the conventional benzodiazepines and sedative-hypnotics. J Pharmacol Exp Ther 291: 1233\u20131241.","DOI":"10.1016\/S0022-3565(24)35232-2"},{"key":"10.1124\/jpet.107.119693_bib27","doi-asserted-by":"crossref","unstructured":"Rowlett JK, Spealman RD, Lelas S, Cook JM, and Yin W (2003) Discriminative stimulus effects of zolpidem in squirrel monkeys: role of GABAA\/\u03b11 receptors. Psychopharmacology 165: 209\u2013215.","DOI":"10.1007\/s00213-002-1275-z"},{"key":"10.1124\/jpet.107.119693_bib28","doi-asserted-by":"crossref","unstructured":"Rowlett JK and Woolverton WL (1997) Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: I. Comparison with triazolam in rhesus monkeys and rats. J Pharmacol Exp Ther 280: 162\u2013173.","DOI":"10.1016\/S0022-3565(24)36360-8"},{"key":"10.1124\/jpet.107.119693_bib29","doi-asserted-by":"crossref","unstructured":"Rudolph U, Crestani F, Benke D, Br\u00fcnig I, Benson JA, Fritschy J-M, Martin JR, Bluethmann H, and M\u00f6hler H (1999) Benzodiazepine actions mediated by specific \u03b3-aminobutyric acidA receptor subtypes. Nature 401: 796\u2013800.","DOI":"10.1038\/44579"},{"key":"10.1124\/jpet.107.119693_bib30","doi-asserted-by":"crossref","unstructured":"Rush CR, Baker RW, and Rowlett JK (2000) Discriminative-stimulus effects of zolpidem, triazolam, pentobarbital, and caffeine in zolpidem-trained humans. Exp Clin Psychopharmacol 8: 22\u201336.","DOI":"10.1037\/\/1064-1297.8.1.22"},{"key":"10.1124\/jpet.107.119693_bib31","doi-asserted-by":"crossref","unstructured":"Rush CR, Baker RW, and Wright K (1999a) Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology 144: 220\u2013233.","DOI":"10.1007\/s002130050997"},{"key":"10.1124\/jpet.107.119693_bib32","doi-asserted-by":"crossref","unstructured":"Rush CR, Frey JM, Griffiths RR (1999b) Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology 145: 39\u201351.","DOI":"10.1007\/s002130051030"},{"key":"10.1124\/jpet.107.119693_bib33","doi-asserted-by":"crossref","unstructured":"Rush CR, Madakasira S, Goldman NH, Woolverton WL, and Rowlett JK (1997) Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans. J Pharmacol Exp Ther 280: 174\u2013188.","DOI":"10.1016\/S0022-3565(24)36361-X"},{"key":"10.1124\/jpet.107.119693_bib34","doi-asserted-by":"crossref","unstructured":"Sanger DJ and Zivkovic B (1986) The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic. Psychopharmacology 89: 317\u2013322.","DOI":"10.1007\/BF00174367"},{"key":"10.1124\/jpet.107.119693_bib35","doi-asserted-by":"crossref","unstructured":"Smith BJ and Bickel WK (2001) Effects of alprazolam, caffeine, and zolpidem in humans trained to discriminate triazolam from placebo. Drug Alcohol Depend 61: 249\u2013260.","DOI":"10.1016\/S0376-8716(00)00145-9"},{"key":"10.1124\/jpet.107.119693_bib36","doi-asserted-by":"crossref","unstructured":"Snodgrass JG, Corwin J (1988) Pragmatics of measuring recognition memory: applications to dementia and amnesia. J Exp Psychol Gen 117: 34\u201350.","DOI":"10.1037\/\/0096-3445.117.1.34"},{"key":"10.1124\/jpet.107.119693_bib37","doi-asserted-by":"crossref","unstructured":"Sullivan SK, Petroski RE, Verge G, Gross RS, Foster AC, and Grigoriadis DE (2004) Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor. J Pharmacol Exp Ther 311: 537\u2013546.","DOI":"10.1124\/jpet.104.071282"},{"key":"10.1124\/jpet.107.119693_bib38","doi-asserted-by":"crossref","unstructured":"Thase ME (2005) Correlates and consequences of chronic insomnia. Gen Hosp Psychiatry 27: 100\u2013112.","DOI":"10.1016\/j.genhosppsych.2004.09.006"},{"key":"10.1124\/jpet.107.119693_bib39","unstructured":"Weerts EM and Griffiths RR (1998) Zolpidem self-injection with concurrent physical dependence under conditions on long-term continuous availability in baboons. Behav Pharmacol 9: 285\u2013297."},{"key":"10.1124\/jpet.107.119693_bib40","doi-asserted-by":"crossref","unstructured":"Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, and Sellers EM (2003) Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. J Clin Psychopharmacol 23: 269\u2013280.","DOI":"10.1097\/01.jcp.0000084031.22282.24"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524340029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524340029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.107.119693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:21:10Z","timestamp":1740003670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524340029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0022356524340029"],"URL":"https:\/\/doi.org\/10.1124\/jpet.107.119693","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.107.119693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}